Paper523360
In vitro synergy and antagonism of antifungal agents against yeast-like fungi.
Dupont B and 1 other. Postgrad Med J, 1979. Cited by 50 papers, by iCite.
Cite this record
ConductScience Library. In vitro synergy and antagonism of antifungal agents against yeast-like fungi. Papers, record 523360. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/523360
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antifungal Agents | Major topic |
| Yeasts | Major topic |
| Drug Evaluation, Preclinical | |
| Drug Synergism |
Source PubMed
References4
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 921134 | [First medical cure of Candida endocarditis on a valve prosthesis]. | Ann Med Interne (Paris) | 1977 | https://conductscience.org/library/papers/921134 | PubMed |
| 2 | 59892 | Letter: Antagonism between miconazole and amphotericin B. | Lancet | 1976 | https://conductscience.org/library/papers/59892 | PubMed |
| 3 | 1101814 | In vitro studies with combinations of 5-fluorocytosine and amphotericin B. | Antimicrob Agents Chemother | 1975 | https://conductscience.org/library/papers/1101814 | PubMed |
| 4 | 5118468 | Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. | Proc Soc Exp Biol Med | 1971 | https://conductscience.org/library/papers/5118468 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41474803 | In vitro evidence to support amphotericin B and flucytosine combination therapy for talaromycosis. | PLoS Negl Trop Dis | 2025 | https://conductscience.org/library/papers/41474803 | PubMed |
| 41040159 | In Vitro Evidence to Support Amphotericin B and Flucytosine Combination Therapy for Talaromycosis. | bioRxiv | 2025 | https://conductscience.org/library/papers/41040159 | PubMed |
| 38960917 | Selective in vitro Synergistic Evaluation of Probiotic Tolerant morpholinyl- and 4-ethylpiperazinyl-Imidazole-chalcone Derivatives on Gastrointestinal System Pathogens. | Curr Microbiol | 2024 | https://conductscience.org/library/papers/38960917 | PubMed |
| 26048362 | Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans. | Virulence | 2015 | https://conductscience.org/library/papers/26048362 | PubMed |
| 16033288 | Antifungal combination therapy: clinical potential. | Drugs | 2005 | https://conductscience.org/library/papers/16033288 | PubMed |
| 14982754 | Combination antifungal therapy. | Antimicrob Agents Chemother | 2004 | https://conductscience.org/library/papers/14982754 | PubMed |
| 8457977 | Compounds active against cell walls of medically important fungi. | Clin Microbiol Rev | 1993 | https://conductscience.org/library/papers/8457977 | PubMed |
| 7486918 | Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/7486918 | PubMed |
| 7363014 | Treating fungal infections. | Br Med J | 1980 | https://conductscience.org/library/papers/7363014 | PubMed |
| 6299182 | Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6299182 | PubMed |
| 6295266 | Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. | Antimicrob Agents Chemother | 1982 | https://conductscience.org/library/papers/6295266 | PubMed |
| 6280603 | Combined activity of ketoconazole and 5-fluorocytosine on potentially pathogenic yeasts. | Antimicrob Agents Chemother | 1982 | https://conductscience.org/library/papers/6280603 | PubMed |
| 3596813 | Problems in antifungal chemotherapy. | Infection | 1987 | https://conductscience.org/library/papers/3596813 | PubMed |
| 3551831 | Entry of ketoconazole into Candida albicans. | Antimicrob Agents Chemother | 1987 | https://conductscience.org/library/papers/3551831 | PubMed |
| 2665643 | Multifactorial analysis of effects of interactions among antifungal and antineoplastic drugs on inhibition of Candida albicans growth. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2665643 | PubMed |
| 2546489 | Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2546489 | PubMed |
| 1416829 | Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1416829 | PubMed |
| 392478 | Fungal endocarditis: patients at risk and their treatment. | Postgrad Med J | 1979 | https://conductscience.org/library/papers/392478 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/523360
GET https://conductscience.org/api/papers/v1/523360/authors